Step Pharma

Our Chief Executive Officer Andy Parker will be attending two upcoming healthcare conferences this September.   Andy will attend the Wells Fargo Healthcare Conference in Boston, followed by the Cantor Fitzgerald Global Healthcare Conference in New York.   If you are interested in learning more about Step Pharma's approach to CTPS1 inhibition and our data-driven 'pipeline in a product' strategy for dencatistat across essential thrombocythaemia, lymphoma and solid tumours, please reach out to connect.   #CantorHealthcare #WellsFargoHealthcare #Oncology #DrugDevelopment #Biotech #Innovation

🩺 Nouvel épisode d'"Une question à mon hémato" ! 👨⚕️ Le Pr. Jean-Jacques Kiladjian, hématologue à hashtag #Paris, aborde aujourd'hui la question : "Quelles analyses de sang (hors NFS plaquettes) est-il intéressant de faire de temps en temps pour vérifier que tout est OK : vitamines, foie, reins, cholestérol, sodium, etc... Comment sont-elles déterminées ?". Ce module est développé grâce au soutien institutionnel de Step Pharma, Novartis et MSD. https://lnkd.in/egPwy9uG #NMP #MPNsm #hematology

We are excited to share that our CEO Andy Parker featured on the latest episode of Beyond Biotech, the podcast by Labiotech.eu, with host Dylan Kissane.   Their discussion included:  • How Andy’s career across pharmaceutical, biotechnology and VC organisations shaped his perspective on drug development  • How dencatistat, our first-in-class CTPS1 inhibitor, targets one novel mechanism relevant across three indications, and how we are progressing a "pipeline in a product" strategy for our lead candidate  • Where Step’s development strategy is heading, with dencatistat recently advancing into phase 2 in essential thrombocythaemia    A big thank you to Dylan for hosting such an engaging conversation!   Listen to the full episode here: https://lnkd.in/eVBUn-qT   #Podcast #DrugDevelopment #Innovation #Biotech #Oncology

We are pleased to announce the appointment of Neil Gallagher MD PhD, as Non-Executive Director, effective immediately.   Neil joins with over 25 years of experience in haematology and oncology across global pharmaceutical companies including Amgen, AstraZeneca, Novartis and AbbVie, where he served as CMO and led multiple regulatory approvals.   His appointment strengthens our board at a pivotal moment, as we advance dencatistat, our first-in-class CTPS1 inhibitor, across three clinical programmes in lymphoma, solid tumours and essential thrombocythaemia, which recently advanced into phase 2.   Welcome to the team, Neil!   Read the full press release here: https://lnkd.in/eDrKpMNR   #BoardAppointment #Leadership #Innovation #Biotech #DrugDevelopment #Oncology #Haematology

Our CEO Andy Parker is heading to San Diego for the BIO International Convention taking place from 22-25 June.   Andy will be attending soon after our recent announcement that dencatistat, our investigational CTPS1 inhibitor, has advanced into a phase 2 trial for essential thrombocythaemia (ET), a rare clonal blood disorder which has seen no new treatments in decades.   If you are attending BIO and are interested in learning more about Step Pharma’s data-driven ‘product in a pipeline’ strategy across ET, multiple solid tumours and blood cancers, please do reach out to connect.   #BIO2026 #CancerResearch #Oncology #Innovation #DrugDevelopment 

Great to see this article by our VP, Clinical Operations, Maureen Higgins featured in Clinical Leader, highlighting how lean, highly collaborative teams can successfully deliver ambitious clinical development programs.   Maureen shares insights from our experience advancing dencatistat across multiple indications while keeping patients, science, and operational excellence at the center of everything we do.   Read the full article below. https://lnkd.in/ge4Q9Cbb

We’re pleased to announce that our investigational first-in-class, highly selective, oral CTPS1 inhibitor, dencatistat, has advanced into a phase 2 clinical trial for essential thrombocythaemia (ET). ET is a rare clonal blood disorder characterised by overproduction of platelets and an increased risk of thrombosis.   This key milestone follows encouraging results from our phase 1b trial which has enrolled participants across all ET mutation subtypes.  The phase 2 trial, named VECTRA, will evaluate the safety, tolerability and efficacy of dencatistat, in up to 50 individuals with high risk ET across sites in the US, EU and UK.   Read the full press release here: https://lnkd.in/eFN58B9W   #ClinicalTrials #EssentialThrombocythaemia #ET #Haematology #Biotech #DrugDevelopment

We are thrilled to have been selected for the 2026 French Tech 120 (FT120) programme, led by LaFrenchTech Paris-Saclay.   This programme recognizes us as one the most promising French start-ups and is validation of our on-going commitment to addressing the need for innovative therapeutics for cancers and blood disorders.   Through our efforts, we are advancing our first-in-class CTPS1 inhibitor, dencatistat, for essential thrombocythaemia, B and T cell lymphomas, and solid tumours.   The FT120 programme grants us access to invaluable operational support from the Mission French Tech team enabling us to effectively deploy our resources and expedite our development pipeline.   #FrenchTech120 #Innovation #CancerResearch #Oncology #DrugDevelopment

Our CEO Andy Parker, CSO Philip Beer, VP Head of Clinical Operations Maureen Higgins and Director Clinical Operations Carol M. are heading to Stockholm to attend the European Hematology Association (EHA) 2026 Congress, taking place from 11-14 June.   At Step Pharma we are committed to advancing a new treatment option for patients living with complex blood cancers and disorders. Our first-in-class CTPS1 inhibitor, dencatistat, is progressing across clinical programmes in lymphoma and essential thrombocythaemia.   We look forward to engaging with the haematology community to discuss the latest developments in the field.   If you are attending the conference and would like to learn more, please reach out and connect.   #EHA2026 #CancerResearch #Oncology #Innovation #DrugDevelopment

Our CEO Andy Parker and CSO Philip Beer are heading to Chicago to attend the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 29 May – 3 June.   ASCO brings together the global oncology community to share the latest advances in cancer research, clinical innovation and treatment development, helping drive progress for patients worldwide.   The team are excited to meet with industry and academic colleagues to discuss our latest progress in advancing CTPS1 inhibition as a precision oncology approach across both solid tumours and blood cancers.   If you are attending the conference and would like to learn more, please reach out and connect.   #ASCO2026 #ASCOAnnualMeeting #CancerResearch #Oncology #Innovation #DrugDevelopment